U.S. appeals court rejects Sequenom bid to restore prenatal DNA test patent

NEW YORK, Dec 2 (Reuters) - In a key decision that could put in doubt the validity of a wide swath of medical and biotechnology patents, a U.S. appeals court on Wednesday refused to reconsider an earlier decision invalidating a Sequenom Inc prenatal DNA test patent, despite conceding it was a "valuable contribution to science."